ETON Stock Forecast & Price Target

Eton Pharmaceuticals is viewed favorably because its 2Q26 results showed record revenue of $37.6M, up 99% YoY and 55% QoQ, with net income of $0.35 per diluted share, far ahead of consensus and strong enough to lift FY26 revenue guidance to at least $145M and adj. EBITDA margin guidance to >35%. The main driver is HEMANGEOL, where about 95% of the inherited ~8,000-patient base converted to the single Eton Cares channel by the end of June, supporting an implied annualized revenue range of roughly $64M-$80M and suggesting management’s guidance may be conservative. Beyond that launch, the company has an increasingly de-risked rare-disease platform with eight commercial products, five late-stage candidates, and repeated bolt-on acquisitions that could extend growth while preserving sufficient capital, given the $26.8M cash balance at the end of 2Q26 and expected positive cash flow.

Eton Pharmaceuticals is challenged by a long history of operating losses, and while it reported positive GAAP net income for the first time in 3Q24, there is no assurance that profitability can be sustained in future periods. Its limited capital base and reliance on PIPEs, public offerings, and expanded credit facilities suggest a need for additional financing if positive cash flow falters, which could constrain aggressive sales and marketing efforts. The outlook is further pressured by uncertainty around product adoption and the risk that late-stage or acquired candidates may fail to generate favorable clinical data or regulatory approval, undermining long-term valuation.